Letters, Statements & Analysis
AMCP communicates the importance of managed care pharmacy by collaborating with members to provide comments, analysis, and testimony to Congress and federal and state agencies on the impact of proposed regulations and laws on managed care pharmacy and patients.
The Academy of Managed Care Pharmacy (AMCP) appreciates the opportunity to provide comments in response to the Centers for Medicare and Medicaid Services’ (CMS’) proposed Revisions to Payment Policies under the Physician Fee Schedule and Other Revisions to Part B for CY 2019; Medicare Shared Savings Program Requirements; Quality Payment Program; and Medicaid Promoting Interoperability Program (CMS-1693-P).
The Academy of Managed Care Pharmacy (AMCP) thanks the Food and Drug Administration (FDA) for the opportunity to provide comments in response to “Patient-Focused Drug Development on Chronic Pain; Public Meeting; Request for Comments” as published in the Federal Register on July 11, 2018.
The Academy of Managed Care Pharmacy (AMCP) supports off‐label use of FDA‐approved drugs when medically appropriate and necessary, but opposes government‐mandated coverage of specific pharmaceuticals, whether for FDA‐approved or off‐label uses.
The Academy of Managed Care Pharmacy (AMCP) is writing in strong support of the “Opioid Crisis Response Act”. The importance of this Act increases as the number of overdose deaths according to the CDC rise (72,000 overdose deaths in 2017).1 As you know, the Act will advance patient treatment and recovery initiatives, improve prevention of opioid addiction, protect communities, and bolster efforts to fight deadly illicit synthetic drugs like fentanyl.
The Academy of Managed Care Pharmacy (AMCP) is writing in strong support of the “Opioid Crisis Response Act”. The importance of this Act increases as the number of overdose deaths according to the CDC rise (72,000 overdose deaths in 2017).
The Academy of Managed Care Pharmacy (AMCP) writes in strong support of requiring electronic transmission of prescriptions (e-Rx) as proposed in Assembly Bill 2789. AMCP believes that the electronic exchange of prescription, drug benefit, and drug information improves patient drug therapy, increases operational efficiencies and optimizes health care outcomes and will decrease abuse and diversion of prescriptions for controlled substances.
We are writing to express our support for the Biosimilars Competition Act of 2018 (H.R. 6478). The undersigned stakeholders share your commitment to promoting a biosimilars market that will help reduce prescription drug costs for patients, payers, and taxpayers. We commend you for introducing this important legislation and look forward to working with you to enact it into law.
AMCP was pleased that the bill, the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act (S. 974), bipartisan legislation designed to increase patient access to safe and affordable generic and biosimilar medicines and marketplace competition, continued to garner bipartisan support when it was voted out of the Judiciary Committee.
The Academy of Managed Care Pharmacy (AMCP) appreciates the opportunity to provide comments in response to the Department of Health and Human Services’ (HHS’s) request for information on the HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs [RIN 0991-ZA49] (Blueprint).
The Academy of Managed Care Pharmacy (AMCP) thanks the Food and Drug Administration (FDA) for the opportunity to provide comments in response to “Drug and Device Manufacturer Communications With Payors, Formulary Committees, and Similar Entities—Questions and Answers [FDA-2016-D-1307]” as published in the Federal Register on June 13, 2018.
The Alliance wants to ensure an FDA that is sized and modernized to meet its mandate in the 21st century. The FDA oversees products that represent 20% of consumer spending in the US and affect every American multiple times each day. Its responsibilities are global in scope and form the backbone of the world’s economy.
On behalf of the Academy of Managed Care Pharmacy (AMCP), I wanted to take this opportunity to express our strong support for the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act (S. 974), bipartisan legislation to increase competition and patient access to safe and affordable generic and biosimilar medicines.
